As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.